Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Xiaolei Liu is active.

Publication


Featured researches published by Xiaolei Liu.


Surgery | 2017

Characteristics and operative treatment of extremely giant liver hemangioma >20 cm

Xiaolei Liu; Zhiying Yang; Haidong Tan; Liguo Liu; Li Xu; Yongliang Sun; Shuang Si; Jia Huang; Wenying Zhou

Background: Giant liver hemangioma >20 cm may cause severe complications; therefore, operative treatment can be highly difficult and risky. No studies have been performed to determine the characteristics of this subgroup. Methods: A retrospective study was performed on 141 patients who underwent operative treatment for liver hemangioma. The patients were divided into an extremely giant hemangioma group (>20 cm, 36 cases) and a giant hemangioma group (>10 cm but <20 cm, 105 cases). A comparison was then made between the groups. For patients in the extremely giant hemangioma group, further comparison was also made between liver resection and enucleation. Results: Compared with the giant hemangioma group, patients in the extremely giant hemangioma group had greater rates of leukopenia (P < .001), anemia (P < .001), thrombocytopenia (P < .001), pancytopenia (P < .001), prolonged prothrombin time (P < .001), and Kasabach‐Merritt syndrome (P = .001). Patients in the extremely giant hemangioma group also had greater rates of compression of the hepatic vein (P < .001), inferior vena cava (P < .001), and porta hepatis (P < .001). The extremely giant hemangioma group had more blood loss (P < .001) and autologous transfusion (P < .001), greater rates of blood transfusion (P < .001), and greater postoperative stays (P < .001). Morbidity was greater in the extremely giant hemangioma group; however, this difference was not statistically significant (P = .076). For patients in the extremely giant hemangioma group, no differences were detected regarding autologous transfusion, blood transfusion, or morbidity between enucleation and liver resection. Conclusion: Extremely giant hemangiomas may cause abnormalities in the hematologic and coagulation systems. Operative treatment may be difficult and risky but can be completed safely.


Medicine | 2017

Giant liver hemangioma with adult Kasabach-Merritt syndrome: Case report and literature review

Xiaolei Liu; Zhiying Yang; Haidong Tan; Li Xu; Yongliang Sun; Shuang Si; Liguo Liu; Wenying Zhou; Jia Huang

Rationale: Adult Kasabach-Merritt syndrome associated with giant liver hemangioma is rare; to date, most reports have been single-case reports, and no multi-case reports or literature reviews are available. Diagnoses: We conducted a retrospective analysis of 5 cases of adult Kasabach-Merritt syndrome associated with giant liver hemangioma treated at our hospital between 2011 and 2016. All 5 patients had varying severities of leukopenia, anemia, thrombocytopenia, prolonged prothrombin time, and hypofibrinogenemia. Interventions: All the patients underwent surgery: 2 patients had left hemihepatectomy; 1 had enucleation; 1 had a right hemihepatectomy; and 1 had a left trisectionectomy. Outcomes: The 5 patients had an average operative time of 6.9 hours and an average blood loss of 3200 mL. One patient developed a biliary fistula (grade II) after the operation. There was no mortality among 5 patients. The white blood cell counts, hemoglobin, platelets, and prothrombin times of all 5 patients returned to normal after the operation. To date, a total of 11 cases of adult Kasabach-Merritt syndrome associated with giant liver hemangioma have been reported, of which 8 patients underwent surgery, and their platelets and coagulation returned to normal after the operation. Lessons: Adult Kasabach-Merritt syndrome associated with giant liver hemangioma is uncommon, and surgical treatment is risky. However, resection of the tumor corrected the abnormalities in hematological and coagulative systems.


Hpb | 2018

Patient age affects the growth of liver haemangioma

Xiaolei Liu; Zhiying Yang; Haidong Tan; Li Xu; Liguo Liu; Jia Huang; Shuang Si; Yongliang Sun; Wenying Zhou

BACKGROUND The aim of this study was to report the prevalence of liver haemangioma and describe growth rates by age. METHODS A retrospective study of people undergoing a health examination. The collected data included gender, age, presence or absence and size of liver haemangioma. A second database of liver haemangioma patients with a minimum follow up period of 5 years was analysed. The collected data included gender, initial age at diagnosis, follow-up period, initial and final size. RESULTS Patients were divided into four age groups: 20-29 years, 30-39 years, 40-49 years and ≥50 years. Patients in the 20-29 years group had the lowest prevalence of liver haemangioma (1.78%) and the smallest size (1.3 ± 0.7 cm), while 40-49 years group had the highest prevalence (3.94%) and largest size (1.9 ± 1.3 cm). Patients between 30 and 39 years had the greatest increase in haemangioma size (4.0 cm, (3.0, 6.0) cm), while patients of ≥50 years had the least (1.4 cm (0.5, 3.8) cm). The proportion of patients without an increase in haemangioma size increased with age (P = 0.031). CONCLUSION Age is an important factor affecting the prevalence and growth rate of liver haemangioma.


Medicine | 2017

Long-term result of transcatheter arterial embolization for liver hemangioma

Xiaolei Liu; Zhiying Yang; Haidong Tan; Jia Huang; Li Xu; Liguo Liu; Shuang Si; Yongliang Sun

Abstract Transcatheter arterial embolization (TAE) is a method for the treatment of liver hemangioma, but fewer studies reported the long-term result. Retrospective study was conducted to liver hemangioma patients who received TAE. The inclusion criteria included the following: the period of follow-up was more than 5 years; and patients were followed up for less than 5 years, but received surgical treatment due to the enlargement of tumor or severe complications of TAE. The collected data included sex, age, size of the tumor, times of TAE, complications, period of follow-up, long-term result, and whether or not surgery was finally performed. Fifty-five patients were included, and the average age was 43.1 ± 8.6 years. The average size of liver hemangioma was 9.0 ± 4.3 cm. Four patients (7.3%) had severe complications after TAE, including 2 cases of biloma which were cured by surgery. The tumor size was smaller or the same in 19 patients after 5 years follow-up, and the long-term effective rate was 35.8%. The size of tumor became larger in the other 34 patients (64.2%), and 29 patients (54.7%) received surgery finally. The long-term effective rate for patients with ≥10 cm tumor and <10 cm tumor were 12.5% and 45.9%, respectively, and the difference was significant (P = .019). The long-term result of TAE for liver hemangioma was not satisfying, and the treatment had the risk of severe complication. For patients with asymptomatic liver hemangioma, TAE should not be conducted.


Medicine | 2016

Intraoperative portal vein insulin assay combined with occlusion of the pancreas for complex pancreatogenous hypoglycemia: Two cases report.

Zhiying Yang; Haidong Tan; Yongliang Sun; Shuang Si; Li Xu; Xiaolei Liu; Liguo Liu; Wenying Zhou; Jia Huang

AbstractIntraoperative localization and confirmation of complete resection of the hypersecreting tissue are the 2 main challenges in the management of pancreatogenous hypoglycemia. Here, we report our experience with intraoperative portal vein insulin assay combined with occlusion of the pancreas in the management of pancreatogenous hypoglycemia. Clinical courses of 2 patients with biochemical evidence of a pancreatogenous hypoglycemia were studied. The preoperative diagnosis was multiple endocrine neoplasia 1 (MEN-1) and nesidioblastosis, respectively. Rapid intraoperative portal vein insulin assay combined with occlusion of the pancreas was used to localize and confirm complete excision of the hypersecreting tissue. Hypoglycemia was successfully treated in both the patients. In the MEN-1 patient, 2 small tumors in the head of pancreas were not resected, as they were deemed noninsulin secreting by intraoperative portal vein insulin assay, thus avoiding a total pancreatectomy. In the patient with nesidioblastosis, using intraoperative portal vein insulin assay combined with occlusion of the pancreas, an appropriate amount of pancreatic tissue was resected thereby avoiding recurrence and diabetes. This technique may be of particular value in patients with complex conditions such as MEN-1 and nesidioblastosis, to localize and achieve complete resection of hypersecreting pancreatic tissue.


Journal of Gastrointestinal Surgery | 2018

Fever of Unknown Origin Caused by Giant Hepatic Hemangioma

Xiaolei Liu; Zhiying Yang; Haidong Tan; Wenying Zhou; Yunchao Su


Journal of Surgical Research | 2016

Differentiation of benign and malignant hilar bile duct stenosis

Xiaolei Liu; Zhiying Yang; Haidong Tan; Chen Shao; Liguo Liu; Shuang Si; Li Xu; Yongliang Sun


International Journal of Clinical and Experimental Pathology | 2015

Hepatocellular carcinoma in nonalcoholic fatty liver disease mimicking benign hemangioma: two case reports and literature review.

Haidong Tan; Li Xu; Xiaolei Liu; Shuang Si; Yongliang Sun; Liguo Liu; Wenying Zhou; Zhiying Yang


Hepatobiliary surgery and nutrition | 2018

Lymphovascular tumor embolus might be a risk factor for peritoneal metastasis after laparoscopic hepatectomy for hepatocellular carcinoma

Zhiying Yang; Xiaolei Liu; Haidong Tan; Liguo Liu


Annals of Pancreatic Cancer | 2018

Case analysis of pancreatic cancer treated with FOLFIRINOX in China

Shuang Si; Zhiying Yang; Haidong Tan; Yongliang Sun; Xiaolei Liu; Li Xu; Liguo Liu; Wenying Zhou; Jia Huang

Collaboration


Dive into the Xiaolei Liu's collaboration.

Top Co-Authors

Avatar

Haidong Tan

China-Japan Friendship Hospital

View shared research outputs
Top Co-Authors

Avatar

Zhiying Yang

China-Japan Friendship Hospital

View shared research outputs
Top Co-Authors

Avatar

Liguo Liu

China-Japan Friendship Hospital

View shared research outputs
Top Co-Authors

Avatar

Yongliang Sun

China-Japan Friendship Hospital

View shared research outputs
Top Co-Authors

Avatar

Li Xu

China-Japan Friendship Hospital

View shared research outputs
Top Co-Authors

Avatar

Shuang Si

China-Japan Friendship Hospital

View shared research outputs
Top Co-Authors

Avatar

Jia Huang

China-Japan Friendship Hospital

View shared research outputs
Top Co-Authors

Avatar

Wenying Zhou

China-Japan Friendship Hospital

View shared research outputs
Top Co-Authors

Avatar

Chen Shao

China-Japan Friendship Hospital

View shared research outputs
Top Co-Authors

Avatar

Yunchao Su

China-Japan Friendship Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge